Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development
Psychedelic Medicine – September 06, 2023
Source: OpenAlex
Summary
A compelling new direction in Psychiatry and Medicine explores Psychedelics and Drug Studies to address Major depressive disorder. Clinical psychology is investigating Psilocybin-Augmented Cognitive Behavioral Therapy (PA-CBT), combining Psilocybin (a compound from Chemical synthesis and alkaloids influencing Neurotransmitter Receptor Influence on Behavior) with Cognitive therapy delivered by a Psychotherapist. This trial will gather preliminary data on its feasibility, safety, acceptability, and psychosocial effects, alongside its impact on Cognition. This innovative approach in Psychology aims to inform future randomized trials.
Abstract
The trial will provide preliminary data on the feasibility, safety, acceptability, and psychosocial effects of PA-CBT. Results will inform randomized clinical trials to test the effects of PA-CBT for patients with depression and other mental health conditions, as well as hypotheses concerning mediating mechanisms at the cognitive and affective levels. ClinicalTrials.gov ID: NCT05227612.